High-flow nasal therapy vs conventional oxygen therapy in mild COVID-19 hypoxaemia: a Bayesian reanalysis of the COVID-HIGH Trial - PubMed
5 hours ago
- #respiratory therapy
- #COVID-19
- #Bayesian analysis
- The study compares high-flow nasal therapy (HFNT) and conventional oxygen therapy (COT) in mild COVID-19 hypoxaemia.
- The COVID-HIGH trial initially showed no significant benefits of HFNT over COT but was underpowered.
- Bayesian reanalysis suggests HFNT likely reduces respiratory support escalation and improves clinical recovery.
- Escalation of respiratory support occurred in 23.6% (HFNT) vs 30.2% (COT), with a risk difference of -6.6%.
- Posterior probability mass on the beneficial side remained high (>70%), while harm side was low (≤6%).
- Clinical recovery at day 14 was 61.5% (HFNT) vs 53.3% (COT), with 61-73% probability of benefit.
- The study was approved by ethics committees and followed Good Clinical Practice guidelines.
- Several authors reported competing interests, including consulting fees and honoraria from medical device companies.